Achilles Therapeutics Plc (ACHL) Stock Price, Quote & News

thefastfreddy Sep. 28 at 6:11 PM

IVDA is the sleeper AI + drone play people will pretend they knew about later. With a tiny float and commercial-ready robotics, it could re-rate hard off any government, defense, or safety contract. Bottomed. Unloved. Loaded. $UBX $QH $SGH $ACHL $VYNE

0 · Reply

WallStVisions Sep. 24 at 11:15 AM

XPON - The lithium wave is real XPON is tied directly to it. Energy storage, home power, marine, RV all real-world growth verticals. Float is small. Chart is coiled. The next PR or volume burst could launch it. $NLST $SNSE $ACHL $BTTX $GLSI

0 · Reply

rastytwits Mar. 27 at 4:25 PM

$ACHL now that it’s delisted from Nasdaq, how do I sell my shares? Missed the delisting notice.

1 · Reply

Laynester Mar. 18 at 2:53 PM

$ACHL Seeing a see of green on $ACHL

0 · Reply

BuyLowSellHigh88 Mar. 14 at 5:46 PM

$ACHL Reasons to Favor TNXP 1. Broad Pipeline: TNXP has a more diversified portfolio targeting multiple conditions, which reduces reliance on a single therapy. 2. Regulatory Progress: TNXP’s lead candidate (TNX-102 SL) is closer to commercialization, with an FDA PDUFA date set for August 2025. 3. Strategic Partnerships: Strong collaborations with Bilthoven Biologicals and X-Chem, Inc. enhance its research capabilities. Key Considerations • Risk: ACHL is riskier due to its narrower focus and recent decision to discontinue key trials, signaling challenges in its pipeline. • Diversification: TNXP’s broader pipeline and advanced regulatory progress make it a more stable choice. Conclusion If you prefer a safer option with near-term catalysts, TNXP may be better. If you’re seeking high-risk, high-reward opportunities in oncology, ACHL could be appealing.

0 · Reply

Scanners_Free Feb. 28 at 12:07 PM

$ACHL NNEEEWS OUT

0 · Reply

ajmrtxl Feb. 18 at 4:41 PM

$ACHL's recent data from Squeezefinder

0 · Reply

PenkeTrading Feb. 5 at 11:05 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Achilles Therapeutics PLC ADR. Is that bullish or bearish? $ACHL #Achilles #RsiOverbought #NASDAQ

0 · Reply

ikkydiphoenix Feb. 4 at 4:07 PM

$ACHL KimAnthony are you still alive? lol

0 · Reply

moonwalker1231 Feb. 4 at 3:47 PM

$CPIX $ACON $EVAX $ACHL $EMPD As I said

0 · Reply

Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

Nov 19, 2024, 7:00 AM EST - 11 months ago

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

Nov 14, 2024, 7:00 AM EST - 11 months ago

Achilles Therapeutics Reports Third Quarter 2024 Financial Results

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Achilles Therapeutics Announces Strategic Update

Aug 14, 2024, 7:00 AM EDT - 1 year ago

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

May 22, 2024, 7:00 AM EDT - 1 year ago

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

May 17, 2024, 5:00 PM EDT - 1 year ago

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

May 8, 2024, 7:00 AM EDT - 1 year ago

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 4, 2024, 6:45 AM EDT - 1 year ago

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Feb 5, 2024, 7:00 AM EST - 1 year ago

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

Dec 18, 2023, 7:00 AM EST - 1 year ago

Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction

Nov 13, 2023, 4:30 PM EST - 2 years ago

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Aug 4, 2023, 7:00 AM EDT - 2 years ago

Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Achilles Therapeutics to Present at Upcoming Conferences

May 10, 2023, 7:15 AM EDT - 2 years ago

Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 10, 2023, 7:00 AM EDT - 2 years ago

Achilles Therapeutics' New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens

Apr 25, 2023, 7:00 AM EDT - 2 years ago

Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

Apr 17, 2023, 8:00 AM EDT - 2 years ago

Achilles Therapeutics to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 7, 2023, 7:00 AM EST - 2 years ago

Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights

Dec 20, 2022, 8:30 AM EST - 3 years ago

Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 18, 2022, 7:14 AM EST - 3 years ago

Achilles Therapeutics: The First Full Position In My Tax Loss Selling Basket

Dec 6, 2022, 6:00 AM EST - 3 years ago

Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022

Nov 30, 2022, 6:05 PM EST - 3 years ago

Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022

Nov 22, 2022, 8:00 AM EST - 3 years ago

Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method

Nov 8, 2022, 7:00 AM EST - 3 years ago

Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Oct 6, 2022, 8:30 AM EDT - 3 years ago

Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy

Aug 9, 2022, 7:00 AM EDT - 3 years ago

Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Jul 21, 2022, 8:00 AM EDT - 3 years ago

Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

Jun 30, 2022, 8:00 AM EDT - 3 years ago

Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

Jun 21, 2022, 8:30 AM EDT - 3 years ago

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

May 10, 2022, 7:00 AM EDT - 3 years ago

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 9, 2022, 7:00 AM EDT - 3 years ago

Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

May 4, 2022, 8:00 AM EDT - 3 years ago

Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

Apr 12, 2022, 7:30 AM EDT - 3 years ago

Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US

Apr 12, 2022, 7:30 AM EDT - 3 years ago

The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse

Apr 4, 2022, 8:00 AM EDT - 3 years ago

Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting

Mar 8, 2022, 8:00 AM EST - 3 years ago

Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Mar 1, 2022, 7:02 AM EST - 3 years ago

Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights

Feb 7, 2022, 7:30 AM EST - 3 years ago

Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

Jan 13, 2022, 7:30 AM EST - 4 years ago

Achilles Therapeutics Provides Business Update and Outlook for 2022

Dec 21, 2021, 8:00 AM EST - 4 years ago

Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

Dec 20, 2021, 8:00 AM EST - 4 years ago

Achilles Therapeutics Added to the NASDAQ Biotechnology Index

Dec 9, 2021, 7:00 AM EST - 4 years ago

Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens

Nov 12, 2021, 8:36 PM EST - 4 years ago

Achilles Therapeutics plc (ACHL) CEO Iraj Ali on SITC & Corporate Update Call (Transcript)

Nov 12, 2021, 7:00 AM EST - 4 years ago

Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT and Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing

Nov 10, 2021, 8:15 AM EST - 4 years ago

Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies

Nov 9, 2021, 8:00 AM EST - 4 years ago

Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Oct 22, 2021, 7:30 AM EDT - 4 years ago

Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Solid Tumor T

Oct 12, 2021, 8:00 AM EDT - 4 years ago

Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium

thefastfreddy Sep. 28 at 6:11 PM

0 · Reply

WallStVisions Sep. 24 at 11:15 AM

0 · Reply

rastytwits Mar. 27 at 4:25 PM

$ACHL now that it’s delisted from Nasdaq, how do I sell my shares? Missed the delisting notice.

1 · Reply

Laynester Mar. 18 at 2:53 PM

$ACHL Seeing a see of green on $ACHL

0 · Reply

BuyLowSellHigh88 Mar. 14 at 5:46 PM

0 · Reply

Scanners_Free Feb. 28 at 12:07 PM

$ACHL NNEEEWS OUT

0 · Reply

ajmrtxl Feb. 18 at 4:41 PM

$ACHL's recent data from Squeezefinder

0 · Reply

PenkeTrading Feb. 5 at 11:05 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Achilles Therapeutics PLC ADR. Is that bullish or bearish? $ACHL #Achilles #RsiOverbought #NASDAQ

0 · Reply

ikkydiphoenix Feb. 4 at 4:07 PM

$ACHL KimAnthony are you still alive? lol

0 · Reply

moonwalker1231 Feb. 4 at 3:47 PM

$CPIX $ACON $EVAX $ACHL $EMPD As I said

0 · Reply

topstockalerts Feb. 4 at 3:47 PM

Top Gainers PT2 $ZONE $PLTR $FLXS $ACON $ACHL Details: https://topstockalerts.com/market-gainers-and-losers/

1 · Reply

topstockalerts Feb. 4 at 3:14 PM

Top Gainers PT2 $ZONE $PLTR $FLXS $ACON $ACHL Details: https://topstockalerts.com/market-gainers-and-losers/

1 · Reply

Schorsch11 Feb. 4 at 2:54 PM

$ACHL They have around 2$/share to distribute. Quarterly burn approx. 20m$ (before cut of workforce) and they got 12.4m for R&D and 12m from Astra. OS approx. 41m. Good Deal and it's much better than positive trial data

0 · Reply

topstockalerts Feb. 4 at 2:34 PM

Morning Movers $ACHL $AMOD $EVAX $QNTM $EMPD

0 · Reply

KimAntony Feb. 4 at 2:23 PM

$ACHL wait for it ... big sell imbalance ... and very quickly back down to below $1.30!

1 · Reply

Market_Max Feb. 4 at 2:20 PM

$TPST Steve Brady, sell this shit for $5 and go the fuck away. Follow $ACHL. Go home.

0 · Reply

Market_Max Feb. 4 at 2:18 PM

$CHRS I would so love for Denny to sell Tori rights right now for $1.50 per share, add to about $2.85 per share cash on hand after closing of the asset sale and disposition of any remaining debts and return cash to shareholders in a liquidation. The would be $4.35 per share for each shareholder. I ABSOLUTELY do not trust Denny & Co to achieve anything worthwhile with the cash they will be getting. I can smell it already. Look at what $ACHL just did Denny. Follow their lead and just go home!

2 · Reply

topstockalerts Feb. 4 at 2:15 PM

$ACHL setting up nicely here

0 · Reply

makny Feb. 4 at 2:11 PM

$ACHL it’s time to cut your losses and preserve whatever money is left. Anyone hoping for a miracle after the liquidation News is in a big surprise. Going below one dollar after open.

0 · Reply

KimAntony Feb. 4 at 2:08 PM

$ACHL just waiting for the huge drop now as soon as the big sell imbalance comes out at 9:25 EST.

0 · Reply

GSP Feb. 4 at 1:57 PM

Gap play watch list for today (con't): $ACHL $ZENA $CPIX $ACON $AMOD .

0 · Reply

Market Cap	60.83M
Revenue (ttm)	0.00
Net Income (ttm)	-69.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,204,100
Avg Vol	1,452,728
Day's Range	N/A - N/A
Shares Out	41.10M
Stochastic %K	77%
Beta	1.25
Analysts	Sell
Price Target	$3.25